Of patients who developed anemia, 5 (11.4%) received erythropoietin-stimulating agents (ESAs) only, 3 (6.8%) received blood transfusions only, and one (2.3%) received both ESA and a blood transfusion. This evidence concerns the gene EPO and anemia (phenotype).